Veve, Michael
154  results:
Search for persons X
?
1

1856. Barriers to Improving Outcomes among People Experienc..:

Parke, Dana M ; Kenney, Rachel M ; Bogojevich, John...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
 
?
 
?
 
?
4

607. Candidemia: Role of T2Candida® compared to Bact/Alert ..:

Birk, Navina K ; Soman, Sana ; Kapur, Nandita...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
 
?
 
?
 
?
 
?
10

1575. Predictors of Negative Clinical Outcomes among Patien..:

Alosaimy, Sara ; Lagnf, Abdalhamid M ; Jorgensen, Sarah...
Open Forum Infectious Diseases.  7 (2020)  Supplement_1 - p. S786-S786 , 2020
 
?
11

1577. Real-World, Multicenter Experience with Eravacycline ..:

Alosaimy, Sara ; Lagnf, Abdalhamid M ; Molina, Kyle...
Open Forum Infectious Diseases.  7 (2020)  Supplement_1 - p. S787-S787 , 2020
 
?
13

200. Real-World Experience with Dalbavancin for Complicated..:

Alosaimy, Sara ; Pearson, Jeffrey ; Veve, Michael...
Open Forum Infectious Diseases.  6 (2019)  Supplement_2 - p. S118-S119 , 2019
 
?
14

2406. "Real-world" Treatment of Multidrug-Resistant (MDR) o..:

Pogue, Jason M ; Kaye, Keith S ; Veve, Michael...
Open Forum Infectious Diseases.  5 (2018)  suppl_1 - p. S719-S719 , 2018
 
?
15

Optimized β-Lactam Therapy Improves Survival in Carbapenem ..:

Flynt, Lauren K ; Kenney, Rachel M ; Veve, Michael...
Open Forum Infectious Diseases.  4 (2017)  suppl_1 - p. S140-S141 , 2017
 
1-15